Flexion Therapeutics (FLXN) Receives Buy Rating from Northland Securities

Northland Securities reiterated their buy rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a report published on Friday, November 10th. Northland Securities currently has a $40.00 price target on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently commented on FLXN. Royal Bank Of Canada reiterated an outperform rating and set a $44.00 price target on shares of Flexion Therapeutics in a report on Thursday, August 10th. Needham & Company LLC reissued a buy rating and issued a $36.00 price objective (up from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. BMO Capital Markets reissued a buy rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Zacks Investment Research cut Flexion Therapeutics from a hold rating to a sell rating in a research report on Tuesday, August 22nd. Finally, ValuEngine raised Flexion Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $98.33.

Shares of Flexion Therapeutics (NASDAQ FLXN) traded up $0.55 during mid-day trading on Friday, reaching $25.20. The company’s stock had a trading volume of 1,316,300 shares, compared to its average volume of 842,708. Flexion Therapeutics has a one year low of $15.96 and a one year high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93.

In other news, insider Michael D. Clayman bought 5,000 shares of Flexion Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the transaction, the insider now directly owns 35,395 shares in the company, valued at $835,322. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Yamo Deniz bought 1,375 shares of Flexion Therapeutics stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average cost of $25.40 per share, with a total value of $34,925.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The disclosure for this purchase can be found here. Insiders bought 13,075 shares of company stock valued at $315,698 over the last three months. 15.98% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Macquarie Group Ltd. lifted its position in Flexion Therapeutics by 0.6% in the second quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after purchasing an additional 338 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Flexion Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after purchasing an additional 513 shares during the period. The Manufacturers Life Insurance Company lifted its position in Flexion Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock worth $441,000 after purchasing an additional 811 shares during the period. ProShare Advisors LLC lifted its position in Flexion Therapeutics by 5.5% in the second quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock worth $379,000 after purchasing an additional 982 shares during the period. Finally, IFP Advisors Inc lifted its position in Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the period. 72.89% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/markets/flexion-therapeutics-inc-flxn-stock-rating-reaffirmed-by-northland-securities/1774249.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Stephen Strasburg May Skip All-Star Games in the Future
Stephen Strasburg May Skip All-Star Games in the Future
Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks


Leave a Reply

 
© 2006-2017 BBNS.